This site is intended for Healthcare Professionals only
Back to CKS

Palliative care Child health

End of life care in children

Last revised in April 2024

End of life care refers to life-limiting conditions, which are illnesses that are expected to result in an early death for a child. It includes advice and support for families.

End of life care in children: Summary

  • A life-limiting condition is one where there is no reasonable hope of cure and from which children or young people die prematurely.
  • End of life care includes the care and support given to a child or young person and their family in the final days, weeks, and months leading up to the child or young person's death and the planning and preparation for this. 
  • In England, there has been a marked rise in the prevalence of children and young people with life-limiting conditions, and this increase is predicted to continue.
    • The prevalence of children with life-limiting conditions rose from 32,975 in 2001/2002 to 86,625 in 2017/2018.
    • It is predicted that there will be between 67.0 and 84.2 per 10,000 children living with a life-limiting condition by 2030.
  • All children and young people with life-limiting conditions should be cared for by a defined multidisciplinary team (MDT) and have a named medical specialist who leads and coordinates their care. 
  • All families should receive a child and family-centred multidisciplinary and multi-agency assessment of their needs as soon as possible after diagnosis or recognition of a life-limiting condition in a child or young person.
  • An Advance Care Plan (ACP) should be developed at an appropriate time for the current and future care of the child or young person. The ACP should consider the beliefs and values of the family and should be: 
    • Regularly reviewed, discussed, and updated (when needed).
    • Shared with the child or young person (if appropriate), their parents or carers, and everyone involved in their care. 
  • The child or young person and their parents or carers should be provided with any information or advice they need, for example, regarding:
    • The condition and what it may mean for them.
    • Their role and participation in Advance Care Planning.
    • The membership of their MDT and the responsibilities of each professional. 
    • The care options available, including specific treatments.
    • Practical arrangements that will be needed after the death of a child or young person.
    • Organ donation (if appropriate).
    • Available resources.
    • Available support (including emotional and psychological support) and how they can access it.
  • When a child or young person is approaching the end of life:
    • Resuscitation should be attempted unless there is a 'do not attempt resuscitation' order in place.
    • Their specific support needs and those of their parents or carers should be addressed.
    • The preferred place of care and place of death should be discussed and agreed upon. The ACP may need to be reviewed and updated. 
    • Distressing symptoms, such as agitation and pain, should be managed.
    • Bereavement support should be offered to the parents or carers both before and after the death of a child or young person. 

Have I got the right topic?

From birth to 17 years.

This CKS topic covers the management of end of life and palliative care for children and young people with life-limiting conditions. 

This topic does not cover the management of children and young people without a life-limiting condition who die unexpectedly (for example, accidental death) or palliative care in adults. There are separate CKS topics on Palliative care - constipation, Palliative care - cough, Palliative care - dyspnoea, Palliative care - general issues, Palliative care - malignant skin ulcer, Palliative care - nausea and vomiting, Palliative care - oral, Palliative cancer care - pain, and Palliative care - secretions.  

The target audience for this CKS topic is healthcare professionals working within the NHS in the UK, and providing first contact or primary healthcare.

How up-to-date is this topic?

Changes

April 2024 — reviewed. A literature search was conducted in April 2024 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to the recommendations have been made, but the topic has been restructured.

Previous changes

August 2020 — minor update. A broken URL link was updated.

August to September 2019 — this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.

Update

New evidence

Evidence-based guidelines

No new evidence-based guidelines since 1 April 2024.

HTAs (Health Technology Assessments)

No new HTAs since 1 April 2024.

Economic Appraisals

No new economic appraisals relevant to England since 1 April 2024.

Systematic reviews and meta-analyses

No new systematic reviews or meta-analysis which reach the CKS threshold for inclusion since 1 April 2024.

Primary evidence

No new primary evidence which reaches the CKS threshold for inclusion published since 1 April 2024.

New policies

No new national policies or guidelines since 1 April 2024.

New safety alerts

No new safety alerts since 1 April 2024.

Changes in product availability

No changes in product availability since 1 April 2024.

Goals and outcome measures

Goals

To support primary healthcare professionals to:

  • Be involved in the development of an Advance Care Plan for children and young people with life-limiting conditions. 
  • Manage the needs of children and young people with life-limiting conditions and those of their parents or carers. 
  • Manage specific care issues in children and young people with life-limiting conditions. 
  • Recognize and manage children and young people with hours or days to live
  • Provide bereavement support for parents and carers.

Outcome measures

No outcome measures were found during the review of this topic.

Audit criteria

No audit criteria were found during the review of this topic.

QOF indicators

No QOF indicators were found during the review of this topic.

QIPP - Options for local implementation

No QIPP indicators were found during the review of this topic.

NICE quality standards

  • Infants, children and young people with a life-limiting condition and their parents or carers are involved in developing an advance care plan.
  • Infants, children and young people with a life-limiting condition have a named medical specialist who leads and coordinates their care.
  • Infants, children and young people with a life-limiting condition and their parents or carers are given information about emotional and psychological support, including how to access it.
  • Infants, children and young people with a life-limiting condition are cared for by a multidisciplinary team that includes members of the specialist paediatric palliative care team.
  • Parents or carers of infants, children and young people approaching the end of life are offered support for grief and loss when their child is nearing the end of their life and after their death.
  • Infants, children and young people approaching the end of life and being cared for at home have 24-hour access to both children's nursing care and advice from a consultant in paediatric palliative care.

[NICE, 2017]

Background information

What is it?

  • Life-limiting and life-threatening conditions are terms used to describe the population of children and young people who may benefit from input from paediatric palliative care services [Fraser, 2020].
    • A life-limiting condition is one where there is no reasonable hope of cure and from which the person dies prematurely (for example, Duchenne muscular dystrophy or neurodegenerative disease) [TSL, 2018].
    • A life-threatening condition is one for which curative treatment may be feasible but can fail (for example, cancer) [TSL, 2018].
    • For the purposes of this CKS topic, the term ‘life-limiting condition’ includes life-limiting and life-threatening conditions.
  • Palliative care for children and young people with life-limiting conditions is an active and total approach to care from the point of diagnosis or recognition throughout the life and death of the child or young person [TSL, 2018; TSL, 2022].
    • It embraces physical, emotional, social, and spiritual elements and focuses on enhancing the quality of life for the child or young person and supporting their family.
    • It includes the management of distressing symptoms, provision of short breaks, and care through death and bereavement.
    • Palliative care can be introduced at any stage of a child or young person’s illness, not just at the end of life.
    • Access to palliative care should not depend on the diagnosis or overall prognosis of the life-limiting condition [NHS England, 2023].
  • Advance Care Plan (ACP) is a formal care plan that includes details on the child or young person’s condition, decisions made with them and their parents or carers (for example, about managing symptoms), and their wishes and ambitions [TSL, 2018].
    • The ACP is a core element of children’s palliative care.
    • The term ‘Anticipatory Care Plan’ is used in Scotland.
  • End of life care includes the care and support given to a child or young person and their family in the final days, weeks, and months leading up to the child or young person's death and the planning and preparation for this [NICE, 2021]. 
    • It focuses on preparing for an anticipated death and managing the end stage of a terminal medical condition, including care during and around the time of death and immediately afterwards [TSL, 2018].
    • It enables the supportive and palliative care needs of the child or young person and their family to be identified and met throughout the last phase of life and into bereavement [TSL, 2018].

How common is it?

  • In England, there has been a marked rise in the prevalence of children and young people with life-limiting or life-threatening conditions, and this increase is predicted to continue.
  •  An observational study used national inpatient hospital data from 2000/2001 to 2017/2018 to estimate the prevalence of children (aged 0–19 years) in England with a life-limiting condition and to predict the future prevalence of this population [Fraser, 2021]. 
    • The prevalence of children with life-limiting conditions rose from 32,975 (26.7 per 10,000 children) in 2001/2002 to 86,625 (66.4 per 10,000 children) in 2017/2018. Using a more restricted definition of a life-limiting condition reduced the prevalence from 66.4 to 61.1 per 10,000 children in 2017/2018.
    • In 2017/2018:
      • The prevalence was highest in the under-1-year age group (226.5 per 10,000 children), but there was a rise in prevalence in all age groups. 
      • The prevalence was significantly higher among boys (72.5 per 10,000 children) than girls (60.0 per 10,000 children), but there was no difference in the rise in prevalence between sexes in the study period.
      • Children with congenital abnormalities had the highest prevalence (27.2 per 10,000 children), followed by those with neurological conditions (10.8 per 10,000 children). However, prevalence increased in all diagnostic groups from 2000/2001 to 2017/2018.
      • The prevalence was highest in the most deprived group (88.6 per 10,000 children). There was a gradient with deprivation, with the lowest prevalence in the least deprived group (48.7 per 10,000 children). There was some evidence of a greater difference in prevalence between the least and most deprived groups over time.
      • The prevalence rose in all ethnic groups, but children of Pakistani origin had the highest prevalence of life-limiting conditions (103.9 per 10,000 children) and children of Chinese origin the lowest (32.0 per 10,000 children). Children from Black and Other Asian groups also had a higher prevalence than the White population. Congenital anomalies had the highest prevalence in all ethnic groups, but prevalence was higher in the Pakistani and Other Asian groups. The prevalence of neurological, haematological and metabolic diagnoses was also higher in the Pakistani population than in the White population.
    • It was predicted that there will be between 67.0 and 84.2 per 10,000 children living with a life-limiting condition in England by 2030.

Management

Scenario: Management

From birth to 17 years.

What are the general principles for managing children and young people with life-limiting conditions?

  • All children and young people with life-limiting conditions should be cared for by a defined multidisciplinary team (MDT) and have a named medical specialist who leads and coordinates their care. 
    • Depending on the needs of the child or young person, the MDT may include:
      • Healthcare professionals from primary, secondary, or tertiary services, including specialists in the child's underlying life-limiting condition, hospice professionals, and members of the specialist palliative care team.
      • Social care practitioners.
      • Educational professionals.
      • Chaplains (experts [with any or no religious beliefs] in religious, spiritual, and/ or pastoral care for patients, families, and staff).
      • Allied health professionals (for example, physiotherapists, occupational therapists, and psychological therapists). 
  • All families should receive a child and family-centred multidisciplinary and multi-agency assessment of their needs as soon as possible after diagnosis or recognition of a life-limiting condition in a child or young person.
    • The assessment should be reviewed at appropriate intervals and should include:  
      • Details of the professionals and services involved with the family.
      • The child or young person's medical information and functional abilities.
      • The child or young person's nursing and personal care, emotional, and educational needs.
      • The family's home circumstances. 
  • Management of children and young people with life-limiting conditions includes:
  • All healthcare professionals managing children and young people with life-limiting conditions should: 
    • Recognize that the child or young person and their parents or carers have a central role in decision-making and care planning. 
    • Discuss and regularly review with the child or young person and their parents or carers how they want to be involved in making decisions about their care (as this varies between individuals, at different times, and depending on the decisions being made).
    • Explain to the child or young person and their parents or carers that their contribution to decisions about their care is very important but that they do not have to make decisions alone as their MDT will also be involved.
    • Recognize that continuity of care is important to children and young people and their parents or carers. Therefore, frequent changes to the healthcare professionals caring for the child or young person should be avoided if possible. 
  • After the death of a child or young person:
    • Relevant documents and databases should be updated to avoid, for example, clinical appointments being offered by mistake.
    • A member of the MDT should promptly arrange for all relevant organizations and people to be informed. 

Communicating with children and young people with life-limiting conditions and their parents or carers

  • When communicating with a child or young person with a life-limiting condition and their parents or carers, healthcare professionals should:
    • Consider the age and level of understanding of the child or young person. When appropriate, use formats such as:
      • One-to-one discussion.
      • Play, art, and music activities.
      • Written materials and pictures.
      • Digital media (for example, social media).
    • Focus on the views of the child or young person and their parents or carers and: 
      • Consider their personal and family situation; religious, spiritual, and cultural beliefs and values; and any special needs, such as communication aids or interpreters. 
      • Explore with them whether, based on their beliefs and values, there are any aspects of care about which they have particular views or feelings.
    • Be sensitive, honest, and realistic.
      • Reassure when appropriate.
      • Discuss any uncertainties about the condition and treatment. 
    • Think about how best to communicate at different stages, such as:
      • When the life-limiting condition is first recognized.
      • When reviewing and developing the Advance Care Plan.
      • If their condition worsens.
      • When the child or young person is approaching the end of life. 
    • Provide information that is:
      • Specific to the family's circumstances.
      • Clearly explained and understandable.
      • Consistent.
      • Up-to-date.
    • Provide information verbally and in writing.

Basis for recommendation

This information is largely based on the National Institute for Health and Care Excellence (NICE) guideline End of life care for infants, children and young people with life-limiting conditions: planning and management [NICE, 2021] and the Together for Short Lives (TSL) charity document  A core care pathway for children with life-limiting and life-threatening conditions [TSL, 2013].

What information and advice should I give children and young people with life-limiting conditions and their parents or carers?

  • When a life-limiting condition is diagnosed, tell the child or young person (if appropriate) and their parents or carers about the condition and what it may mean for them.
    • Ask how they would like to discuss the life-limiting condition, for example:
      • Ask which topics they feel are important and would particularly want information on.
      • Ask whether there are topics they do not want detailed information on and discuss their concerns.
      • If appropriate, ask parents or carers whether they think their child understands their condition and its management and which professional their child would like to talk to about it.
      • If appropriate, ask parents or carers what they think their child should be told about their condition.
      • Discuss with the child or young person and their parents or carers their right to confidentiality and how information about their condition will be shared.
    • Review these issues with them regularly because their feelings and circumstances may change over time, and they may need different information at different times.
    • Be aware that most people want to be fully informed about the condition and its management and value information that is specific to their circumstances, consistent, up-to-date, and communicated appropriately (verbally and in writing). Some people may be anxious about receiving information about their condition. 
  • Provide the family with the information they need on: 
  • Discuss the practical arrangements that will be needed after the death of their child or young person, and provide this information in writing. This should cover matters such as:
    • The care of the body.
    • Relevant legal considerations, including.
      • The involvement of the child death overview panel. 
      • The involvement of the coroner.
      • Registration of the death.
    • Funeral arrangements.
    • Post-mortem examination (if this is to be performed).
  • Be alert for signs or situations that the child or young person and their parents or carers need more information or discussions. For example, if:
    • They are more anxious or concerned.
    • The child or young person's condition deteriorates.
    • A significant change to the treatment plan is needed.
  • Ensure that all parents or carers are given the information and opportunities for discussion that they need.

Organ and tissue donation

  • Talk to the child or young person and their parents or carers about organ or tissue donation.
    • Explore their views and feelings about organ and tissue donation.
    • Explain which organs or tissues (if any) may be possible to donate.
    • Involve the organ donation service if needed.
    • The National Institute for Health and Care Excellence (NICE) guideline on Organ donation for transplantation has detailed information on organ donation, including donor identification and consent and when and how to discuss the topic.
  • If organ or tissue donation is not possible, explain why.
  • If the child is eligible to donate organs or tissue, ask them if they and their parents or carers would like to discuss this. If they do:
    • Discuss how deciding to donate could affect their care, for example, by changing their preferred place of care and place of death.
    • Explain the practical policies and procedures involved.
    • Provide written information if needed.
  • If the child does not have the capacity to decide about organ and tissue donation, ask their parents or carers to make the decision.

Preferred place of care and place of death

  • Discuss and agree with the child or young person and their parents or carers about a preferred place of care and place of death. During the discussion, consider:
    • Their wishes, which are personal and individual.
    • Their religious, spiritual, and cultural values.
    • The views of relevant and experienced healthcare professionals.
    • Safety and practicality.
  • Explain that the place of care or place of death may change, for example:
    • If the child or young person or their parents or carers change their minds.
    • For clinical reasons.
    • Due to problems with service provision. 
  • Provide information on:
    • The various care settings (for example, home, hospice, or hospital care).
    • The care and support available in each setting.
    • Practical and safety issues.
  • If care at home is preferred, consider and discuss the practical issues, such as the possible need for:
    • Home adaptations.
    • Changes to living arrangements.
    • Equipment and support.
  • For children who are being cared for at home, services should provide (when needed):
    • Advice from a consultant in paediatric palliative care (for example, by telephone) at any time (day and night).
    • Paediatric nursing care at any time (day and night).
    • Home visits by a healthcare professional from the specialist paediatric palliative care team (for example, for symptom management).
    • Practical support and equipment for interventions, including oxygen, enteral nutrition, and subcutaneous and intravenous therapies. 
    • Anticipatory prescribing for children who are likely to develop symptoms.
  • If it is suspected that a child or young person may die soon and they are not in their preferred place of death, consider whether rapid transfer is possible and in the child or young person's best interests. Discuss this with the child or young person and their parents or carers.
    • When planning a rapid transfer to the preferred place of death: 
      • Be aware that the course of their condition may be unpredictable and that they may die sooner or later than expected.
      • Discuss any uncertainties about the course of their condition and how this could affect their care with them and their parents/carers.
      • Ensure that relevant changes to the Advance Care Plan are implemented.
    • Think about using a rapid transfer process to allow the child or young person to be in their preferred place of death when withdrawing life-sustaining treatments, such as ventilation.
    • Before rapid transfer, agree with the parents or carers where the body of the child or young person will be cared for after their death. 

Basis for recommendation

These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline End of life care for infants, children and young people with life-limiting conditions: planning and management [NICE, 2021].

How should I be involved in Advance Care Planning?

  • All children and young people with life-limiting conditions should have an Advance Care Plan (ACP) in their medical record. This should not be confused with a 'do not attempt resuscitation' order. 
    • Develop and record an ACP:
      • At an appropriate time for the current and future care of the child or young person. 
      • In discussion with relevant members of the multidisciplinary team (MDT), the child or young person (if appropriate), and their parents or carers. 
    • If there is an antenatal diagnosis of a life-limiting condition:
      • Begin discussing an ACP with parents during the pregnancy.
      • Consider who should be involved in the discussion, for example, obstetricians, midwives, neonatologists, specialists in the life-limiting condition, and/or a member of the specialist paediatric palliative care team. 
  • The ACP should include:
    • Demographic information about the child or young person and their family. 
    • Up-to-date contact information for:
      • The child or young person's parents or carers.
      • The key professionals involved in care.
    • A statement about who has responsibility for giving consent.
    • A summary of the life-limiting condition.
    • An agreed approach to communicating with and providing information to the child or young person and their parents or carers.
    • An outline of the child or young person's life ambitions and wishes, for example, on:
      • Family and other relationships.
      • Social activities and participation.
      • Education.
      • How to incorporate their religious, spiritual, and cultural beliefs and values into their care.
    • A record of significant discussions with the child or young person and their parents or carers, including any discussions and decisions that have taken place on:
    • Agreed treatment plans and objectives.
    • Education plans, if relevant.
    • A distribution list for the ACP.
  • When developing an ACP:
    • Recognize that the child or young people and their parents or carers are central in decision-making and care planning. 
      • Consider their beliefs and values when developing the ACP.
      • Explain that their contribution to decisions is very important but that they do not have to make decisions alone as their MDT will also be involved. 
      • Ask whether there are other people important to them (such as friends, boyfriends or girlfriends, teachers, or foster parents) who they would like to be involved and, if so, how they would like those people to provide a supporting role. 
    • Discuss with the child or young person and their parents/carers:
      • The nature of the life-limiting condition. Ask how they would like to discuss the life-limiting condition.
      • The expected benefits and possible harms of the management options.
      • How they want to be involved in making decisions about their care (as this may vary between individuals, at different times, and depending on what decisions are being made). Review this regularly.
    • Use parallel planning to account for possible unpredictability in the course of the condition.
      • This involves making multiple plans for care and using the one that best fits the child or young person's circumstances at the time.
    • Explain to the child or young people and their parents/carers that Advance Care Planning should:
      • Help them be involved in planning their care and give them time to think about their views carefully.
      • Help them to understand the life-limiting condition and its management. 
      • Help to prepare for possible future difficulties or complications.
      • Support continuity of care, for example, if there are changes in the professionals involved or the care setting (such as a hospital admission or discharge).
    • If the child or young person is approaching the end of life:
      • Discuss with the parents or carers about the care and support they can expect when the child dies. Discuss their personal needs and feelings about this.
  • Share the ACP with the child or young people (if appropriate) and their parents/carers.
    • Consider which professionals and services involved in the child or young person's care should also see it, for example, GPs, hospital consultants, hospices, respite centres, nursing services (community or specialist), school and other education services, and/or ambulance services.  
  • Review the ACP regularly (in discussion with relevant members of the MDT, the child or young person [if appropriate], and their parents/carers).
    • Update the ACP when needed, for example, if new professionals become involved, the care setting changes (for example, hospital admission or discharge), or the child or young person and their parents or carers move home.
      • Discuss the changes with the child or young person (if appropriate) and their parents or carers.
      • Share the ACP with everyone involved each time it is updated. 
    • Be aware that any existing resuscitation plan may need to be changed in some circumstances, for example, if the child or young person is undergoing general anaesthesia. 
  • If it is suspected that a child or young person is approaching the end of life, review and, if necessary, update the ACP (in discussion with relevant members of the MDT, the child or young person [if appropriate] and their parents or carers). The updated ACP should include a record of:
    • Any intended changes to care and when they should happen, for example, rapid transfer to the preferred place of death.
    • Care plans that cover:
      • The final hours or days of life.
      • What will happen if the child or young person lives longer than expected.
      • Care and support for the family after the child or young person dies.
      • Care of the child's or young person's body after death.
    • The professionals who will be involved and their responsibilities.
    • The professionals who will help with the practical and administrative arrangements after the death. 

Basis for recommendation

These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline End of life care for infants, children and young people with life-limiting conditions: planning and management [NICE, 2021].

How should I care for a child or young person who is approaching the end of life?

  • When a child or young person is approaching the end of life (likely to die within weeks):
    • Attempt resuscitation unless there is a 'do not attempt resuscitation' order in place.
    • Review and, if necessary, update the Advance Care Plan (ACP), including the preferred place of care and place of death.  
      • Be aware that discussing the ACP can be distressing for the child or young person and their parents or carers, and they may be reluctant to think about end of life care, have difficulties discussing it with the professionals or one another, or have differences of opinion about the care plan.
      • Discuss with the parents/carers about the care and support they can expect when the child dies. Discuss their personal needs and feelings about this.
      • When difficult decisions must be made about end of life care, give children and young people and their parents or carers enough time and opportunities for discussions. 
    • Think about and discuss the specific support needs of the child or young person and their parents or carers. Review these needs regularly.
    • Be aware of the importance of talking about dying, and if appropriate, discuss:
      • Whether they want and are able to talk about this.
      • Whether they or their parents or carers would like support in talking to each other about this.
    • Take into account the beliefs, values, and wishes of children or young person and their parents or carers when thinking about:
      • The possibility of treatment withdrawal.
      • Funeral arrangements and the care of the body after death.
    • Discuss with parents or carers what would help them, for example:
      • Important rituals.
      • Recording or preserving memories (for example, with photographs, hair locks, or hand prints).
      • Plans for social media content.
  • When assessing whether a child or young person is likely to die within hours or days:
    • Recognize that there are various symptoms and signs (individually or in combination) that indicate that a child or young person is likely to die within hours or days.
    • Monitor these symptoms and signs non-invasively as far as possible:
    • Consider:
      • The wider clinical context, including the normal clinical baseline, past clinical events (such as previous episodes of temporary deterioration), and the overall progression of their condition.
      •  The clinical judgement of healthcare professionals experienced in end of life care.
    • If the child or young person or their parents or carers feel that they are likely to die within hours or days, be aware that they may be correct. Discuss their concerns with them.
  • When a child or young person is likely to die within hours or days:
    • Support them and their parents or carers by:
      • Listening to any fears or anxieties.
      • Showing empathy and compassion.
    • Be aware that the child or young person or their parents or carers may not express their feelings openly and may:
      • Have intense and varied feelings, such as fear, hopelessness, or anger. 
      • Become more accepting of the inevitability of death.
    • Give the child or young person and their parents or carers opportunities to talk. 
    • Explain to the child or young person and their parents or carers:
      • Why you think the child or young person is likely to die within hours or days and any uncertainties.
      • What clinical changes can be expected.
      • Whether you think the treatment plan should be changed. 
    • Provide care as specified in the ACP or review if needed.  
    • Be aware that the child or young person or their parents or carers may have difficulty asking directly if a child or young person is dying.
      • Explore and discuss their concerns if you think they want to talk about this.
    • Discuss with them and their parents or carers and with relevant healthcare professionals: 
      • Any available invasive treatments that might be in their best interest. 
      • Any interventions they are currently receiving that may no longer be in their best interest.
    • If withdrawing a treatment, explain to the child or young person and their parents or carer that it is often difficult to tell if or how this may affect them, or when they will die.
    • Ensure that the child or young person can have private time with their parents or carers.
    • If it is suspected that a child or young person may die soon and they are not in their preferred place of death, consider whether rapid transfer is possible and in the child or young person's best interests. Discuss this with the child or young person and their parents or carers.

Symptoms and signs common in the last hours or days of life

  • Symptoms and signs that are common in the last hours or days of life include:
    • A change of breathing pattern (for example, noisy, laboured, or irregular breathing).
    • Impaired peripheral perfusion (which can be indicated by a pale or grey appearance or a prolonged capillary refill time), including temperature instability.
    • Loss of interest in or ability to tolerate drinks or food.
    • A marked and unexplained fall in urine output.
    • An altered level of awareness (for example, reduced consciousness, alertness or responsiveness, excessive sleeping, or confusion).
    • Intractable seizures that keep occurring even with optimal management.
    • New onset of profound weakness.
    • Increasing pain and need for analgesia.

Basis for recommendation

These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline End of life care for infants, children and young people with life-limiting conditions: planning and management [NICE, 2021].

How should I manage distressing symptoms in children and young people with life-limiting conditions?

Managing agitation

  • As children and young people with life-limiting conditions approach the end of life, they may:
    • Become agitated (shown by restlessness, irritability, aggressive behaviour, crying, or other distress).
    • Show signs of delirium (such as confusion, disrupted attention, disordered speech, and hallucinations).
  • If a child becomes agitated or delirious: 
    • Make sure that they are safe from physical injury.
    • Look for causes and factors that may be contributing to this, including:
      • Medical disorders and conditions, such as pain, hypoxia, anaemia, dehydration, urinary retention, or constipation.
      • Psychological factors, such as fear, anxiety, or depression.
      • Adverse effects of medication.
    • Be aware that in children and young people with a neurological disability, signs and symptoms of agitation or delirium can be mistaken for the signs and symptoms of seizures or dystonia.
  • If a child or young person who is approaching the end of life needs treatment for agitation:
    • Identify and, if possible, treat any medical or psychological conditions that may be contributing to it. 
    • Consider non-pharmacological interventions, such as:
      • Calm speaking, reassurance, distraction, and physical contact (such as holding and touch).
      • Changes to the environment to make it more comfortable, calm, and reassuring (such as reducing noise and lighting, maintaining a comfortable room temperature, and providing familiar objects and people and relaxing music).
      • Religious and spiritual support if this is wanted and helpful.
    • Consider pharmacological interventions (beginning with low doses and increasing if necessary), for example: 
      • Benzodiazepines (such as midazolam, diazepam, or lorazepam).
      • Neuroleptics (such as haloperidol or levomepromazine).

Managing pain

  • Assess for the presence and severity of pain. 
    • Be aware that various factors can contribute to pain, including: 
      • Biological factors, such as musculoskeletal disorders or constipation.
      • Environmental factors, such as an uncomfortable or noisy care setting.
      • Psychological factors, such as anxiety or depression.
      • Social, emotional, religious, spiritual, or cultural considerations. 
    • For children and young people who have pain or have had it before, regularly reassess for pain and severity even if they are not receiving treatment for it.
  • When assessing pain in children and young people:
    • Use an age-appropriate approach that takes account of their stage of development and ability to communicate.
    • Try to identify what is causing or contributing to their pain. Be aware that:
      • The pain may not be related to the life-limiting condition.
      • Pain, discomfort, and distress may be caused by a combination of factors, which will need an individualized management approach. 
    • Take into account the following causes of pain and distress that might have been overlooked, particularly in children and young people who cannot communicate:
      • Neuropathic pain (for example, associated with cancer).
      • Gastrointestinal pain (for example, associated with diarrhoea or constipation). 
      • Bladder pain (for example, caused by urinary retention).
      • Bone pain (for example, associated with metabolic diseases).
      • Pressure ulcers.
      • Headache (for example, caused by raised intracranial pressure).
      • Musculoskeletal pain (particularly if they have neurological disabilities).
      • Dental pain.
  • Consider non-pharmacological interventions for pain management, such as:
    • Changes that may help them to relax, for example:
      • Environmental adjustments (such as reducing noise).
      • Music.
      • Physical contact (such as touch, holding, or massage).
    • Local hot or cold applications to the site of pain.
    • Comfort measures, such as sucrose for neonates.
  • When tailoring pain treatment, consider the views of the child or young person and those of their parents or carers on:
    • The benefits of pain treatment.
    • The possible adverse effects of analgesia for moderate to severe pain (for example, unwanted sedation, reduced mobility, or constipation).
  • Consider using a stepwise approach to analgesia based on pain severity and persistence:
    • For mild pain, consider paracetamol or ibuprofen sequentially and then in combination if needed.
    • For moderate to severe pain, also consider one of the following options:
      • Low-dose oral opioids (such as morphine).
      • Transmucosal opioids.
      • Subcutaneous opioids.
      • Intravenously infused opioids (if a central venous catheter is in place).
  • When using opioids, titrate treatment to find the minimal effective dose that will relieve and prevent pain.
    • Calculate opioid doses using weight rather than age because the child or young person may be underweight for their age.
    • Titrate treatment to provide continuous background analgesia; prescribe additional doses for breakthrough pain if this occurs.
    • If treatment with a specific opioid does not give adequate pain relief or if it causes unacceptable adverse effects, consider an alternative opioid.
  • In addition to background analgesia, consider giving anticipatory doses of analgesia to children or young people who have pain at predictable times (for example, when changing dressings or during moving and handling).
    • Do not include anticipatory doses when calculating the required daily background dose of analgesia.
  • If neuropathic pain is suspected and standard analgesia is not helping, consider a trial with one of the following:
    • Gabapentin. 
    • A low-dose tricyclic antidepressant (for example, amitriptyline).
    • An anti-N-Methyl-D-aspartate (NMDA) agent (for example, ketamine or methadone [used under guidance from a specialist]).

Managing respiratory distress

  • If a child has respiratory distress, breathlessness, or noisy breathing:
    • Explain that these symptoms are common. 
    • Discuss the likely causes or contributing factors.
    • Discuss any treatments that may help.
  • Consider and, if possible, treat the likely contributing factors or causes. If these are likely to be caused by:
    • Anxiety:
      • Discuss why they are anxious. 
      • Reassure them and manage their anxiety accordingly. 
      • Consider breathing techniques and guided imagery. 
      • Consider anxiolytic drugs.
    • Physical discomfort:
      • Consider what could be causing the discomfort (for example, their position) and, if possible, help them with it.
    • Environmental factors:
      • Consider environmental changes, such as changing the room temperature.
    • Accumulated airway secretions:
      • Consider repositioning, airway suctioning, physiotherapy, or anti-secretory drugs.
    • Medical disorders, for example, pneumonia, heart failure, sepsis, or acidosis:
      • Use appropriate interventions, such as bronchodilators, nebulized saline, opioids, or oxygen supplementation.
  • If further assessment is required, consider referral to an appropriate specialist (for example, a respiratory or cardiac specialist).

Managing seizures

  • If a child has a seizure, look for and, if possible, treat or remove any potential causes, triggers, or contributing factors, for example:
    • Fever.
    • Electrolyte disturbances.
    • Drug reactions.
    • Sleep deprivation.
    • Pain.
    • Excessive environmental stimulation.
  • If a child is thought to be at increased risk of seizures (for example, because they have had seizures before or because of an existing brain disorder): 
    • Include seizure management in their Advance Care Plan.
    • Consider the benefits and drawbacks of specific seizure treatments and:
    • Explain to the child or young person and their parents or carers:
      • How likely it is that they may have a seizure.
      • What they might notice if a seizure happens.
      • That seizures can be frightening or upsetting.
      • What parents or carers should do if a seizure occurs at home (for example, place the child in a safe position).
  • Be aware that abnormal movements (such as dystonic spasms) might be mistaken for seizures.
    • If in doubt, seek specialist advice.
  • If parents or carers have been provided with anticonvulsive treatment (such as buccal midazolam):
    • Ensure they know how and when to use it if the child or young person has a seizure at home.

Ensuring adequate hydration

  • If a child or young person with a life-limiting condition is approaching the end of life or is dying (likely to die in hours or days):
    • Discuss how to manage their fluid with them and their parents/carers.
    • Encourage and support them to drink if they want to and are able to.
    • Continue to provide the child with lip and mouth care.
  • If a child cannot drink, discuss whether starting or continuing enteral tube or intravenous (IV) fluids is in their best interests.
    • Be aware that enteral tubes and intravenous fluids may have a significant effect on care, be a burden for the child or young person, and mean the preferred place of care and place of death need to be changed.
    • Review the decision to give enteral or IV fluids regularly to ensure it continues to be in their best interests. 

Ensuring adequate nutrition

  • If a child or young person with a life-limiting condition is approaching the end of life or is dying (likely to die in hours or days):
    • Discuss how to manage their nutritional needs with them and their parents (or carers).
    • Encourage and support them to eat if they want to and are able to.
  • If the child or young person is receiving enteral tube feeding or intravenous nutrition:
    • Discuss whether continuing this is in their best interest and review this decision regularly.

Basis for recommendation

These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline End of life care for infants, children and young people with life-limiting conditions: planning and management [NICE, 2021].

What support should I offer the family?

  • Provide information on the emotional and psychological support available and how to access it. 
  • If needed, provide information on social and practical support and religious, spiritual, and cultural support.
  • Be aware that:
    • Siblings will need support to cope with their brother's or sister's condition and death, as well as the effects of their parents' or carers' grieving. This may include social, practical, psychological, and spiritual support. 
    • Other family members (for example, grandparents) and people important to the child or young person (for example, friends, boyfriends, or girlfriends) may need support. This may include social, practical, emotional, psychological, and spiritual support. 
  • Offer bereavement support from a professional with appropriate expertise to the parents or carers both before and after the death of a child or young person. 

Emotional and psychological support

  • Be aware that:
    • Children and young people with life-limiting conditions and their parents or carers: 
      • May have emotional and psychological distress and crises, relationship difficulties, and mental health problems. 
      • May need support (and sometimes expert psychological intervention) to help with distress, coping, and building resilience. 
    • Children and young people with life-limiting conditions may experience rapid changes in their condition and so might need emergency interventions and urgent access to psychological services. 
    • Children and young people with learning difficulties or problems with communication may have specific emotional and psychological difficulties.
  • Regularly discuss emotional and psychological wellbeing with children and young people and their parents or carers, particularly at times of change, such as:
    • When the life-limiting condition is diagnosed.
    • If their clinical condition deteriorates.
    • If their personal circumstances change.
    • If there are changes to their nursery care, school or college arrangements, or employment.
    • If there are changes to their clinical care, for example, if their care changes focus from treating the condition to end of life care.

Social and practical support

  • Be aware that children and young people with life-limiting conditions and their parents or carers have varied social and practical support needs and that those needs may change during the course of their condition. This may include:
    • Material support, for example, housing or adaptations to their home, or equipment for home drug infusions. 
    • Practical support, such as access to respite care.
    • Technical support, such as training and help with administering drug infusions at home.
    • Education support, for example, from hospital school services.
    • Financial support.

Religious, spiritual, and cultural support

  • Ask children and young people with life-limiting conditions and their parents/carers if they want to discuss the beliefs and values (for example, religious, spiritual, or cultural) that are important to them and how these should influence their care. 
    • Take account of these beliefs and values in all discussions with them and when making decisions about their care.
    • The charity Together for Short Lives has developed a Diversity Toolkit to support professionals and organizations to consider diversity and cultural issues in children’s palliative care.
  • Be aware that:
    • Some people find discussions about their beliefs and values difficult or upsetting, while others find them reassuring and helpful. Some may need to discuss their beliefs and values more than once.
    • Children and young people may feel differently from their parents, carers, or healthcare professionals about how their beliefs and values should influence their care. If there is disagreement, try to make a mutually acceptable care plan, and if necessary, involve the chaplaincy service or another facilitator.

Bereavement support

  • When a child or young person with a life-limiting condition is approaching the end of life:
    • Discuss the bereavement support available with parents or carers and provide written information.
    • Talk to the parents or carers about available psychological bereavement support groups.
    • Offer bereavement support from a professional with appropriate expertise to the parents or carers both before and after the death of a child or young person. 
    • Be aware that siblings should also be offered bereavement support because not only are they affected by the loss of a brother or sister, but they also have to cope with the impact it has on the family and the relationships within it. 
  • When planning bereavement support for parents or carers:
    • Talk to them about the support that is available, and explore with them what they would find helpful and acceptable.
    • Consider what support different professionals could provide (for example, their GP or healthcare professionals who know the child and are involved in their care).
    • Think about the role of individual professionals in providing specific aspects of support.
    • Inform the multidisciplinary team about the support plan.
  • When making a bereavement support plan with parents or carers, discuss possible options with them, such as:
    • Opportunities to talk to the professionals caring for the child or young person to:
      • Discuss memories and events.
      • Answer any concerns or questions they may have.
    • Home visits from the healthcare professionals caring for the child. 
    • Bereavement support groups.

Basis for recommendation

These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline End of life care for infants, children and young people with life-limiting conditions: planning and management [NICE, 2021].

Supporting evidence

This CKS topic is largely based on the National Institute for Health and Care Excellence (NICE) guideline End of life care for infants, children and young people with life-limiting conditions: planning and management [NICE, 2021].

How this topic was developed

This section briefly describes the processes used in developing and updating this topic. Further details on the full process can be found in the About Us section and on the Clarity Informatics website.

Search strategy

A literature search was conducted for guidelines and systematic reviews on end of life care in children in primary care. 

Search dates

August 2019 - April 2024

Key search terms

The terms listed below are the core search terms that were used for EBSCOhost MEDLINE (searched 2nd August 2019). These were combined with filters to identify guidelines, systematic reviews and primary care relevant literature in EBSCOhost MEDLINE. The strategy was adapted for The Cochrane Library databases. 

S23    S15 AND S22 
S22    S16 OR S17 OR S18 OR S19 OR S20 OR S21 
S21    AB ( (adolescen* or teen* or youth* or juvenile* or minors or child* or schoolchild* or preschool* or toddler* or boy* or girl* or paediatric* or pediatric* or infant* or infancy OR baby or babies or newborn* or neonat*) ) OR TI ( (adolescen* or teen* or youth* or juvenile* or minors or child* or schoolchild* or preschool* or toddler* or boy* or girl* or paediatric* or pediatric* or infant* or infancy OR baby or babies or newborn* or neonat*) ) 
S20    (MH "Pediatrics+") 
S19    (MH "Infant+") 
S18    (MH "Child+") 
S17    (MH "Minors") 
S16    (MH "Adolescent") 
S15    S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 
S14    AB dying OR TI dying 
S13    AB hospice* OR TI hospice* 
S12    AB palliat* OR TI palliat* 
S11    AB (end n2 life) OR TI (end n2 life) 
S10    AB ( (terminal* N2 (care or caring)) ) OR TI ( (terminal* N2 (care or caring)) ) 
S9    AB ( ((terminal* or advanced or incurable or life-limit* or life-threaten*) N2 (ill* or disease* or condition* or phase* or stage*)) ) OR TI ( ((terminal* or advanced or incurable or life-limit* or life-threaten*) N2 (ill* or disease* or condition* or phase* or stage*)) ) 
S8    (MH "Hospice and Palliative Care Nursing") 
S7    (MH "Palliative Medicine") 
S6    (MH "Hospice Care") 
S5    (MH "Palliative Care") 
S4    (MH "Terminal Care+") 
S3    (MH "Advance Directives+") 
S2    (MH "Resuscitation Orders") 
S1    (MH "Terminally Ill") 

Sources of guidelines

Sources of systematic reviews and meta-analyses

  • The Cochrane Library:
    • Systematic reviews
    • Protocols
    • Database of Abstracts of Reviews of Effects
  • Medline (with systematic review filter)
  • EMBASE (with systematic review filter)

Sources of health technology assessments and economic appraisals

Sources of randomized controlled trials

  • The Cochrane Library:
    • Central Register of Controlled Trials
  • Medline (with randomized controlled trial filter)
  • EMBASE (with randomized controlled trial filter)

Sources of evidence based reviews and evidence summaries

Sources of national policy

Patient experiences

Sources of medicines information

The following sources are used by CKS pharmacists and are not necessarily searched by CKS information specialists for all topics. Some of these resources are not freely available and require subscriptions to access content.

Stakeholder engagement

Our policy

The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:

  • Clinical accuracy.
  • Consistency with other providers of clinical knowledge for primary care.
  • Accuracy of implementation of national guidance (in particular NICE guidelines).
  • Usability.

Principles of the consultation process

  • The process is inclusive and any individual may participate.
  • To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.
  • Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.
  • Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.
  • External reviewers are not paid for commenting on the draft topics.
  • Discussion with an individual or an organization about the CKS response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).
  • All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.
  • All reviewers are invited to be acknowledged on the website. All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.

Stakeholders

  • Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the Getting involved section of the Clarity Informatics website.
  • Stakeholders identified from the following groups are invited to review draft topics:
    • Experts in the topic area.
    • Professional organizations and societies (for example, Royal Colleges).
    • Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer’s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.
    • Guideline development groups where the topic is an implementation of a guideline.
    • The British National Formulary team.
    • The editorial team that develop MeReC Publications.
  • Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.

Patient engagement

Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:

  • Topic selection
  • Scoping of topic
  • Selection of clinical scenarios
  • First draft internal review
  • Second draft internal review
  • External review
  • Final draft and pre-publication

Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.

Evidence exclusion criteria

Our policy

Scoping a literature search, and reviewing the evidence for CKS is a methodical and systematic process that is carried out by the lead clinical author for each topic. Relevant evidence is gathered in order that the clinical author can make fully informed decisions and recommendations. It is important to note that some evidence may be excluded for a variety of reasons. These reasons may be applied across all CKS topics or may be specific to a given topic.

Studies identified during literature searches are reviewed to identify the most appropriate information to author a CKS topic, ensuring any recommendations are based on the best evidence. We use the principles of the GRADE and PICOT approaches to assess the quality of published research. We use the principles of AGREE II to assess the quality of published guidelines.

Standard exclusions for scoping literature:

  • Animal studies
  • Original research is not written in English

Possible exclusions for reviewed literature:

  • Sample size too small or study underpowered
  • Bias evident or promotional literature
  • Population not relevant
  • Intervention/treatment not relevant
  • Outcomes not relevant
  • Outcomes have no clear evidence of clinical effectiveness
  • Setting not relevant
  • Not relevant to UK
  • Incorrect study type
  • Review article
  • Duplicate reference

Organizational, behavioural and financial barriers

Our policy

The CKS literature searches take into consideration the following concepts, which are discussed at the initial scoping of the topic.

  • Feasibility
    • Studies are selected depending on whether the intervention under investigation is available in the NHS and can be practically and safely undertaken in primary care.
  • Organizational and Financial Impact Analysis
  • Studies are selected and evaluated on whether the intervention under investigations may have an impact on local clinical service provision or national impact on cost for the NHS. The principles of clinical budget impact analysis are adhered to, evaluated and recorded by the author. The following factors are considered when making this assessment and analysis.
    • Eligible population
    • Current interventions
    • Likely uptake of new intervention or recommendation
    • Cost of the current or new intervention mix
    • Impact on other costs
    • Condition-related costs
    • In-direct costs and service impacts
    • Time dependencies
  • Cost-effectiveness or cost-benefit analysis studies are identified where available. 

We also evaluate and include evidence from NICE accredited sources which provide economic evaluations of recommendations, such as NICE guidelines. When a recommended action may not be possible because of resource constraints, this is explicitly indicated to healthcare professionals by the wording of the CKS recommendation.

Declarations of interest

Our policy

Clarity Informatics requests that all those involved in the writing and reviewing of topics, and those involved in the external review process to declare any competing interests. Signed copies are securely held by Clarity Informatics and are available on request with the permission of the individual. A copy of the declaration of interest form which participants are asked to complete annually is also available on request. A brief outline of the declarations of interest policy is described here and full details of the policy is available on the Clarity Informatics website. Declarations of interests of the authors are not routinely published, however competing interests of all those involved in the topic update or development are listed below. Competing interests include:

  • Personal financial interests
  • Personal family interest
  • Personal non-financial interest
  • Non-personal financial gain or benefit

Although particular attention is given to interests that could result in financial gains or losses for the individual, competing interests may also arise from academic competition or for political, personal, religious, and reputational reasons. An individual is not obliged to seek out knowledge of work done for, or on behalf of, the healthcare industry within the departments for which they are responsible if they would not normally expect to be informed.

Who should declare competing interests?

Any individual (or organization) involved in developing, reviewing, or commenting on clinical content, particularly the recommendations should declare competing interests. This includes the authoring team members, expert advisers, external reviewers of draft topics, individuals providing feedback on published topics, and Editorial Steering Group members. Declarations of interest are completed annually for authoring team and editorial steering group members, and are completed at the start of the topic update and development process for external stakeholders.

Competing interests declared for this topic:

None.

References

Change privacy settings